Pituitary cancer, also known as adenohypophysial cancer, originates from the pituitary gland located at the base of the brain. It is a rare form of cancer that accounts for less than 1% of brain and central nervous system tumors. The dominant symptoms of pituitary cancer include headaches, vision problems, and hormonal issues. Conventional treatment methods for pituitary cancer involve surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy and immunotherapy. Surgery is usually the primary treatment approach with the goal of removing as much of the tumor as possible. However, a complete resection is difficult due to the gland's position and infiltration into surrounding tissues.

The global pituitary cancer market is estimated to be valued at US$ 457.31 Mn in 2024 and is expected to exhibit a CAGR of 9.6% over the forecast period 2024 to 2031.

The rising incidence of pituitary adenomas, increasing demand for targeted therapies, and advancements in diagnostic and imaging techniques are the key factors estimated to drive the market growth. Targeted therapies used for pituitary cancer inhibit specific molecular pathways involved in tumor growth and have fewer side effects than chemotherapy.

Key Takeaways
Key players operating in the pituitary cancer market are Novartis International AG, Pfizer Inc., Ipsen Biopharmaceuticals, Inc., Endocyte, RECORDATI GROUP, Camurus AB, Endeavor Biomedicines, Inc., and Debiopharm International SA. Key players are focusing on developing novel targeted therapy drugs through clinical trials.

The Pituitary Cancer Market Demand  adenomas and increasing adoption of targeted therapies are fueling the demand for pituitary cancer treatment. According to the World Health Organization, pituitary adenomas account for 10-15% of all primary brain tumors.
The market is witnessing rapid global expansion with growing awareness and increased healthcare expenditure in developing economies such as China, India, and Brazil. The availability of advanced diagnostic procedures and targeted therapy drugs is driving the adoption in these emerging markets.

Market Drivers
Pituitary Cancer Market Size And Trends funding for rare cancers: Rare cancers like pituitary adenomas are gaining prominence due to substantial government and private funding for research. This has accelerated target identification, drug development and clinical trials.

For instance, Novartis' Signifor is a targeted therapy approved by the FDA for Cushing's disease and acromegaly.
Growing geriatric population: Aging is a significant risk factor for pituitary tumors. The rising life expectancy globally is expected to increase the prevalence of pituitary adenomas. According to the WHO, the number of people over 60 years will nearly triple to more than 2 billion by 2050. This is anticipated to generate high demand for pituitary cancer therapies over the coming decade.

Get More Insights On, Pituitary Cancer Market